Bey-Liing Mau M.D.

General Internal Medicine
Medical Team: Breast Cancer

Current Title

  • Attending Physician, Division of General Internal Medicine, 2002-present


  • General internal medicine

Clinical Interests

  • General internal medicine
  • Preventive medicine
  • Women's health

Languages Spoken

  • Mandarin Chinese
  • English

Education and Training

1977-1984 Kaohsiung Medical School, Taiwan, MD, Medicine
1986-1991 Mayo Graduate School, Rochester, MN, USA, PhD, Pharmacology
1992-1993  Internship, University of Tennessee, Memphis, TN, USA 
1993-1995  Residency, University of Tennessee, Memphis, TN, USA

Professional Experience

3/1996-9/1998 Physician, Internal Medicine, Methodist Primary Care Association, USA
11/1999-7/2002 Director of Clinical Division, Center for Drug Evaluation, Taiwan
7/2002-present Attending Physician, Internal Medicine, Koo Foundation Sun Yat-Sen Cancer Center, Taiwan

Professional Memberships

  • Member, Taiwan Society of Internal Medicine

Selected Publications

  1. Mau B.-L. and Powis, G.: Mechanism-based inhibition of thioredoxin reductase by antitumor quinoid compounds. Biochem Pharmacol (England) 43: 1613-1620, 1992.
  2. Mau B.-L. and Powis, G.: Inhibition of cellular thioredoxin reductase by diaziquone and doxorubicin Relationship to the inhibition of cell proliferation and decreased ribonucleotide reductase activity. Biochem Pharmacol (England), 43: 1621-1627, 1992.
  3. Lin YL, Mau BL, Chern HD, Chu ML. What type of pivotal study design is appropriate for an investigational drug to manage chronic angle closure glaucoma? Drug Info J 36; 499-500, 2002.
  4. Yeong-Liang Lin, MD, chia-Hsin Huang, MD, Chih-Liu Lin, MD, and Bey-Liing Mau, MD, PHD, Compliance of clinical trial consent forms with international guidelines: Analysis of deficiencies. Drug Info J  36: 17-19, 2002
  5. Tzen C-Y and Mau B-L: Analysis of CD117-Negative Gastrointestinal Stromal Tumors. World J Gastroenterol 11: 1052-1055, 2005
  6. Mau B-L, Lee H-M, and Tzen C-Y: Identification of Human-specific Adaptation Sites of ATP6. AnnuNYAcad Sci1042: 142-147, 2005
  7. C-Y Tzen, B-L Mau, Y-W Huang, M-J Huang and C-P Chen: Is extramedullary plasmacytoma an oligoclonal tumor with clonal selection during tumor progression? Histopathology 48:463-477, 2006
  8. Tzen C-Y, Mau B-L, ­and Hsu H-J: Analysis of disease-associated ND4 mutations: How do we know which mutation is pathogenic? Mitochondrion7:151-156, 2007
  9. Tzen C-Y, Mau B-L, and Wu T-Y: ND4 mutation in transitional cell carcinoma: Does mitochondrial mutation occur before tumorigenesis? Mitochondrion7:273-278, 2007
  10. Tzen C-Y, Wang M-N, and Mau B-L: Spectrum and Prognostication of KIT and PDGFRA Mutation in Gastrointestinal Stromal Tumors. Eur J Surg Oncol 34:563-568, 2008.
  11. Lai Y-L, Mau B-L, Cheng W-H, Chen H-M, Chiu H-H, and Tzen C-Y:  PIK3CA Exon 20 Mutation is Independently Associated with a Poor Prognosis in Breast Cancer Patients. Ann Surg Oncol15:1064-1069, 2008
  12. Mau B-L, Huang Y-W, Wu C-Y, and Tzen C-Y: Diffuse Large B Cell Lymphomas in the Intestine and Lung: Two Lymphomas or Lymphoma Spread? Clin Mol Med 1: 30-32, 2008
  13. 褚乃銘、毛蓓領:專家對談-侵襲性乳癌之標靶治療。生物醫學2008;1:153-157。
  14. 毛蓓領:乳癌療法的回顧與分子指標。生物醫學2009;2:162-172。
  15. 毛蓓領:專家評論-糖尿病的藥物治療。生物醫學2010;3:369-373。
  16. 毛蓓領:胃腸胰神經內分泌瘤的症狀與治療。生物醫學2011;4:43-56。
Copyright © Koo Foundation Sun Yat-Sen Cancer Center 125 Lih-Der Road, Pei-Tou District, Taipei, Taiwan. Tel:+886 2 2897-0011